MarketBeat
26 Sept 2026, 20:02 UTC · 2h ago
Verdict
Headline takes no side. We score ACIU +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
AC Immune reported that its Phase II Part 1 study of ACI-7104.056 met primary safety, tolerability, and immunogenicity objectives in 34 participants.
Newreported results in the article published 2026-09-26
So whatSuccess in this early phase justifies the jump to a 250-patient Part 2 trial, increasing the probability of clinical success for the program.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
The company plans to initiate Part 2 of the trial with approximately 250 patients in the first half of the following year.
Newreported results in the article published 2026-09-26
So whatThe shift from 34 to 250 patients represents a nearly 7.4x increase in trial scale, which will significantly increase R&D burn through H1 2027.
More positive than 79% of claims this week
Exploratory data showed stabilization of CSF total alpha-synuclein and neurofilament light levels in treated participants compared to the placebo group.
Newreported results in the article published 2026-09-26
So whatWhile not statistically significant, positive biomarker trends often lead to higher valuation multiples for clinical-stage biotech prior to efficacy readouts.
More positive than 66% of claims this week
AC Immune will discuss the design of the next phase with the FDA under a recently granted Fast Track designation.
Priced inrefers to designation 'recently granted'
So whatFast Track status may accelerate the timeline for potential BLA filing by reducing the required review time by 60 days.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported positive Phase II trial results meeting primary safety and immunogenicity objectives for its Parkinson's treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
22h ago
—
ACIU hasn't traded since this ran. Last close $2.52 (Sep 25); the reaction starts at the next open.
ACIU chart →
